Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Citi analysts adjusted their outlook on Eisai Co Ltd (OTC:ESAIY). (4523:JP) (OTC: ESALY), reducing the price target from JPY6,000 to JPY5,000, while continuing to endorse the stock with a Buy rating.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

The Scottish Medicines Consortium announced lecanemab would not be made available on the NHS, following a similar decision ...

The first drug proven to slow down Alzheimer's won't be available to dementia patients in Scotland - unless they pay £60,000 ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...